JAK2 and ovarian cancer: In contrast, significant inhibition in cell motility was observed within 14 h (Figure 6D) in EGF-treated cells in the presence of AG490 (100 μM), indicating that JAK2/STAT3 pathway may be involved in the EGF-induced motility of ovarian cancer cells.